Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH 2017 | Adapting AML treatment for elderly patients

Lars Bullinger • 12 Oct 2017
ESH 2017
Acute Myeloid Leukemia Azacitidine Decitabine Venetoclax

The effective use of the correct medication can greatly improve the chance of remission for patients with acute myeloid leukemia (AML). In this insightful video, Lars Bullinger, MD, from Charité University of Medicine, Berlin, Germany, speaking from the International Conference of Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Hematology (ESH), highlights the optimal combination therapies to combat AML in elderly patients and speculates about the future of this area.

More from Lars Bullinger

1:49
Bringing precision medicine and MRD into clinical strategies
Lars Bullinger • 15 Jun 2020
1:56
Minimal gene panel in AML
Lars Bullinger • 15 Jun 2020
2:09
EHA: AML immuno-oncology updates
Lars Bullinger • 15 Jun 2020
1:36
Innovations in MDS and AML treatment
Lars Bullinger • 15 Jun 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals